Literature DB >> 16677855

Clinical correlates of index values in the focus HerpeSelect ELISA for antibodies to herpes simplex virus type 2 (HSV-2).

Rhoda Ashley Morrow1, Elizabeth Krantz, David Friedrich, Anna Wald.   

Abstract

BACKGROUND: Clinical correlates of HerpeSelect ELISA index values are poorly understood.
OBJECTIVES: This study was designed to determine the effects of time of infection, test variability, and antibody avidity on index values. STUDY
DESIGN: Sera (N=313) from 81 patients with new HSV-2 infections and 236 sera from 32 patients with long-standing (median 11.3 years) HSV-2 were tested by HerpeSelect HSV-2 ELISA. High positive, low positive and negative controls were run on 42 test plates to establish test variability.
RESULTS: Index values tended to rise after infection, peaking a median of 9-10 weeks post-infection (range 8-323 days). Of 32 patients with established HSV-2 infections, 7 (22%) had at least one low index value (>1.1 to < or =3.5), and one had a transient seroreversion event. Test variability of index values was substantially lower than inter- or intra-patient variability. Median antibody avidity was higher in sera with high versus low index values in established infections, but unrelated to index value in patients with early infections.
CONCLUSIONS: Index values or index value changes are not absolute indicators of early versus established HSV-2 infection or solely a function of test variability. Low antibody avidity may contribute to low index values once infection is established.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16677855     DOI: 10.1016/j.jcv.2006.02.006

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  7 in total

1.  The Regai Dzive Shiri project: results of a randomized trial of an HIV prevention intervention for youth.

Authors:  Frances M Cowan; Sophie J S Pascoe; Lisa F Langhaug; Webster Mavhu; Samson Chidiya; Shabbar Jaffar; Michael T Mbizvo; Judith M Stephenson; Anne M Johnson; Robert M Power; Godfrey Woelk; Richard J Hayes
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

2.  Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2.

Authors:  Jérôme LeGoff; Philippe Mayaud; Gérard Gresenguet; Helen A Weiss; Khonde Nzambi; Eric Frost; Jacques Pepin; Laurent Belec
Journal:  J Clin Microbiol       Date:  2008-04-02       Impact factor: 5.948

3.  Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings.

Authors:  Jérôme LeGoff; Gérard Grésenguet; Chrysostome Gody; Jean De Dieu Longo; Nzambi Khonde; Helen A Weiss; Philippe Mayaud; Laurent Bélec
Journal:  Clin Vaccine Immunol       Date:  2011-05-11

4.  Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.

Authors:  Alison C Roxby; Alison L Drake; Francisca Ongecha-Owuor; James N Kiarie; Barbra Richardson; Daniel N Matemo; Julie Overbaugh; Sandra Emery; Grace C John-Stewart; Anna Wald; Carey Farquhar
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

5.  Prevalence and incidence estimation of HSV-2 by two IgG ELISA methods among South African women at high risk of HIV.

Authors:  Irith De Baetselier; Joris Menten; Vicky Cuylaerts; Khatija Ahmed; Jennifer Deese; Lut Van Damme; Tania Crucitti
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

6.  Poverty, food insufficiency and HIV infection and sexual behaviour among young rural Zimbabwean women.

Authors:  Sophie J S Pascoe; Lisa F Langhaug; Webster Mavhu; James Hargreaves; Shabbar Jaffar; Richard Hayes; Frances M Cowan
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

7.  Computational sensing of herpes simplex virus using a cost-effective on-chip microscope.

Authors:  Aniruddha Ray; Mustafa Ugur Daloglu; Joslynn Ho; Avee Torres; Euan Mcleod; Aydogan Ozcan
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.